CDK4 and neoplasm: Thus, Formisano et al. have performed a next generation sequencing of circulating tumor DNA in 34 patients after the progression on CDK4/6 inhibitors and have identified FGFR1/2 amplification or activating mutations in 41% post-progression specimens [186].